Chief Business Officer, DTx Pharma
Peter Condon has more than 20 years of experience in corporate development, commercial planning, and operations. Most recently Peter served as the CBO of DTx Pharma, a company focused on the development of oligo therapeutics for rare diseases, where he led pharma partnering, fundraising, portfolio planning and corporate communications. He executed Novartis’ $1B acquisition of DTx by leading all aspects of pharma outreach, due diligence and negotiations. Prior to DTx, Peter held positions as the Vice President and Head of Business Development at Gossamer Bio, and senior roles in business development and commercial planning at Calico Life Sciences, Alexion Pharmaceuticals, and Genentech. Mr. Condon was also responsible for several key corporate transactions across therapeutic areas, including rare diseases, inflammation, and oncology. In addition, he founded an independent consultancy where he advised emerging biotech companies on strategy, capital raising, and operations.